Norwegian Exact Therapeutics Appoints Rafiq Hasan as CEO

Bayer veteran tasked with driving commercialization of proprietary Acoustic Cluster Therapy(ACT®)-based pipeline at EXACT Therapeutics, formerly known as Phoenix Solutions


OSLO, JUNE 3, 2020 EXACT THERAPEUTICS AS, a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announced it has appointed Dr Rafiq Hasan as CEO. He joins as the GE Healthcare spin-out, formerly known as Phoenix Solutions, reports strong progress in its First in Man ACTivate-trial (NCT04021277), investigating ACT® combination with standard of care chemotherapy for the treatment of hepatic metastases secondary to colorectal and pancreatic cancers.


“We are thrilled to attract a world-leading pharma professional and physician of Rafiq’s stature, to propel EXACT to the next level of achievement”, said Sir William Castell, Vice-Chairman of EXACT Therapeutics. “Encouraged by the initial results of our ongoing Phase I trial, we are progressing towards our Phase II. Rafiq joins us at a critical time when we are increasingly focused on the commercial potential for Acoustic Cluster Therapy (ACT®). His in-depth appreciation of clinical development, market access and commercialisation will be invaluable in successfully driving forward the ACT® platform”


Dr Hasan gained his medical degree in London and has pursued a highly successful career in the pharma industry globally, including senior positions with Bayer and Novartis. He has a proven track record of leading global cross-functional teams to manage multi-billion dollar global franchises and deliver year on year sales growth. Most recently as SVP and Global Head of Ophthalmology at Bayer, Dr Hasan grew the business of Eylea® from launch to over USD 2.5bn in 5 years, including its launch in 5 indications in 3 years.


Dr Hasan commented: “There has been tremendous progress in the last 8 years within the field of microbubbles and sonoporation, driven forward by ACT® and EXACT Therapeutics. Through its targeted delivery, ACT® has the potential to enhance therapeutic efficacy of a multitude of products across numerous therapeutic areas. This is some of the most exciting science I have seen with the potential to have a transformative impact on medicine and patients, and I could not pass up this opportunity to lead EXACT Therapeutics into its next phase. I am impressed with the preclinical data where ACT® shows efficacy across a range of drugs and disease models, whilst the clinical development is already underway in London, in partnership with the Royal Marsden Hospital/the Institute of Cancer Research.”


About EXACT Therapeutics AS
"Delivering therapy EXACTLY where it is needed"
EXACT is a clinical stage Norwegian biotech company spun out of GE Healthcare in 2012, currently developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to ultrasound-mediated, targeted drug enhancement – capable of significantly amplifying the clinical utility of a wide range of therapeutic agents across a multitude of indications. Its primary mode of action is modifying vascular permeability, enhancing extravasation and increasing drug distribution and uptake in the targeted tissue. ACT® is being evaluated for diseases where current clinical practice treats known, localized pathologies (such as solid tumors, localized bacterial infections) with approved medicinal therapy, and where standard of care is limited by an inability to deliver sufficiently high concentrations of drug to the target tissue. Click here to watch the video. []


This media statement contains certain forward-looking statements relating to the business, financial performance and results of EXACT Therapeutics, their proprietary ACT® technology, the ACTivate trial and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, “expects”, “intends”, “anticipates”, “targets”, and similar expressions. The forward-looking statements contained in this statement, including assumptions, opinions and views of the company or cited from third party sources are solely opinions and forecasts, which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the company nor any of its directors, officers or employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in this statement or the actual occurrence of the forecasted developments.

The company assumes no obligation, except as required by law, to update any forward-looking statements or to conform these forward-looking statements to our actual results.



For more information contact:


Dr Masha Stromme, Chair EXACT Therapeutics


Richard Hayhurst/Janet Joy RHApr

Tel +44 7711 821527

To read more People News articles, click here.